Novel treatment approaches for patients with relapsed and refractory multiple myeloma.

Current Treatment Options in Oncology
Rajni Sinha, Sagar Lonial

Abstract

Treatment options for patients with relapsed myeloma are a rapidly moving entity. Although autologous transplantation has improved outcomes for younger patients, the use of a second autologous transplant in the relapsed setting has less benefit. Nonmyeloablative allogeneic transplant is being studied in several large cooperative group trials, but to date early auto/mini-allo does not appear to be superior to tandem autologous transplantation. The greatest benefit in the relapsed setting has been demonstrated using novel targeted agents with biologically based therapies. The response rates from thalidomide with and without dexamethasone, bortezomib, and lenalidomide with and without dexamethasone clearly demonstrate high levels of activity with encouraging durations of remission. More recent studies are combining novel agents, and small phase I/II trials are demonstrating higher overall response and complete remission rates. The next generation of novel agents targeting heat shock proteins, the mitogen-activated protein kinase pathway, and monoclonal antibodies are further expanding the list of future potential agents. The rapid clinical development of targeting agents will give us more options to treat patients with relapsed or...Continue Reading

References

Mar 1, 1991·The Journal of Experimental Medicine·E P SampaioG Kaplan
Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·R J D'AmatoJ Folkman
Jun 1, 1993·The Journal of Experimental Medicine·A L MoreiraG Kaplan
Mar 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P HilgardJ Engel
Nov 24, 1999·The New England Journal of Medicine·S SinghalB Barlogie
Sep 20, 2000·Mayo Clinic Proceedings·S V RajkumarP R Greipp
Aug 28, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A DimopoulosN Anagnostopoulos
Feb 21, 2002·The Journal of Prosthetic Dentistry·Kijvanç AkçaMurat C Cehreli
Apr 18, 2002·The Hematology Journal : the Official Journal of the European Haematology Association·Ramón García-SanzJesús Fernando San Miguel
Nov 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert Z OrlowskiSteven L Soignet
Dec 12, 2002·Bone Marrow Transplantation·C-K LeeG Tricot
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Donna WeberRaymond Alexanian
Apr 5, 2003·Cancer Cell·Jennifer S IsaacsLen Neckers
Jun 5, 2003·British Journal of Haematology·Athanasios AnagnostopoulosRaymond Alexanian
Jun 27, 2003·The New England Journal of Medicine·Paul G RichardsonKenneth C Anderson
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Choon-Kee LeeGuido Tricot
Aug 7, 2003·Proceedings of the National Academy of Sciences of the United States of America·Ann-Hwee LeeLaurie H Glimcher
Sep 8, 1962·British Medical Journal·S P WARD
Mar 30, 2004·The Hematology Journal : the Official Journal of the European Haematology Association·Meletios A DimopoulosAthanasios Anagnostopoulos
May 4, 2004·Nature Reviews. Cancer·Julian Adams
Jun 11, 2005·Blood·Vibeke HvidbergSøren K Moestrup
Jun 17, 2005·The New England Journal of Medicine·Paul G RichardsonUNKNOWN Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators
Jun 23, 2005·British Journal of Cancer·M Amit-VazinaZ Estrov
Oct 20, 2005·Blood·Constantine S MitsiadesKenneth C Anderson
Jan 19, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James R BerensonRegina Swift
Jun 5, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Franck MorschhauserBertrand Coiffier

❮ Previous
Next ❯

Citations

Jun 5, 2007·Current Problems in Cancer·Christopher R FlowersOtis W Brawley

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.